Longer duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
Patients with acute lymphoblastic leukemia who received vincristine-based regimens with TKIs did not experience more chemotherapy-induced peripheral neuropathy vs those who did not.
Adolescents and young adults who have cancer also have a negative body image, financial toxicity, and concerns about family planning.
A nonrestrictive diet was found to be noninferior to a protective diet in the post-stem cell transplant setting, suggesting that lifting restrictions may improve patient quality of life.
Patients with metastatic non-squamous non–small cell lung cancer who received frontline dostarlimab (Jemperli) plus chemotherapy experienced a risk of disease progression or death that was 30% greater than that experienced with pembrolizumab (Keytruda).
As the treatment paradigm continues to evolve, nurses play a key role in educating patients, monitoring treatments, and watching for adverse effects.
Atezolizumab has been granted FDA approval for patients aged 2 years and older with unresectable or metastatic alveolar soft part sarcoma.
Treatment with chemotherapy, including taxane-based chemotherapies, in the adjuvant setting did not yield significant differences in breast-cancer related lymphedema risk.
Adagrasib has received accelerated approval for KRAS G12C mutated non–small cell lung cancer. The prescribing label comes with warnings for gastrointestinal toxicities, QTC interval prolongation, hepatotoxicity, and interstitial lung disease.
Lenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.
In real-world practice, use of ovarian suppression therapy was not common among premenopausal patients with hormone receptor–positive, HER2-positive breast cancer, with tamoxifen being the preferred endocrine therapy.
Real-world data from patient-reported outcomes suggest that axicabtagene ciloleucel is associated with temporary worsening of quality of life with statistically and clinically significant improvements within 1-year postinfusion.
Adding daratumumab to bortezomib, lenalidomide, and dexamethasone showed meaningful improvements in patient-reported outcomes in the phase 2 GRIFFIN trial.
In the second-line setting, patients with advanced HER2-positive breast cancer derived a superior clinical benefit with trastuzumab deruxtecan compared with treatment with physician’s choice of treatment.
Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.
Findings from the POSITIVE trial suggest that pausing endocrine therapy to pursue pregnancy did not negatively affect outcomes for patients with breast cancer.
A landmark 4-year analysis of invasive-disease free survival outcomes from the phase 3 monarchE study support the use of adjuvant abemaciclib with endocrine therapy for patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer.
Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
The new model of care will seek to increase value-based care for patients receiving chemotherapy.
New findings suggest that neoadjuvant therapy with antibody-drug conjugates may be effective for patients with early-stage breast cancer.
Improve care for LGBTQ+ patients with cancer by learning about disparities, focusing on patient-centered treatment, and not making assumptions about patients and their loved ones.
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.
Sometimes nurses inappropriately handle high-risk medications. It is important that other nurses, especially those who work in pain management, hold colleagues accountable to promote patient safety.
Adjuvant pembrolizumab demonstrated significantly better quality of life outcomes for patients with resected melanoma vs standard care.
Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
All 24 patients with Merkel cell carcinoma who received nivolumab plus ipilimumab responded to treatment, and 41% achieved complete responses.
Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.
Researchers with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and the University’s Frost School of Music are using a $2.6 million federal grant to study how mindfulness and music therapy can alleviate stress, anxiety, and depression, reduce treatment-related symptoms, and improve quality of life for cancer patients and survivors.
The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.
Nurse investigators created an enteral nutrition standardized pathway for pediatric patients about undergoing hematopoietic stem cell transplantation.
